Your browser doesn't support javascript.
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro.
Murray, Jackelyn; Hogan, Robert J; Martin, David E; Blahunka, Kathy; Sancilio, Fred D; Balyan, Rajiv; Lovern, Mark; Still, Richard; Tripp, Ralph A.
  • Murray J; Department of Infectious Diseases, University of Georgia, Athens, GA, USA.
  • Hogan RJ; Department of Infectious Diseases, University of Georgia, Athens, GA, USA.
  • Martin DE; TrippBio, Inc., Jacksonville, FL, USA.
  • Blahunka K; TrippBio, Inc., Jacksonville, FL, USA.
  • Sancilio FD; Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, FL, USA.
  • Balyan R; Certara, Princeton, NJ, USA.
  • Lovern M; Certara, Princeton, NJ, USA.
  • Still R; TrippBio, Inc., Jacksonville, FL, USA.
  • Tripp RA; Department of Infectious Diseases, University of Georgia, Athens, GA, USA. ratripp@uga.edu.
Sci Rep ; 11(1): 18085, 2021 09 10.
Article in English | MEDLINE | ID: covidwho-1402129
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Virus Replication / Probenecid / Epithelial Cells / SARS-CoV-2 / Lung Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-97658-w

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Virus Replication / Probenecid / Epithelial Cells / SARS-CoV-2 / Lung Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-97658-w